0000000000955804

AUTHOR

F. Javier Chorro

showing 2 related works from this author

Effects of inspiratory muscle training in patients with heart failure with preserved ejection fraction

2013

Heart failure with preserved ejection fraction (HFpEF) is remarkably common in elderly people with highly prevalent comorbid conditions. Despite its increasing in prevalence, there is no evidence-based effective therapy for HFpEF. We sought to evaluate whether inspiratory muscle training (IMT) improves exercise capacity, as well as left ventricular diastolic function, biomarker profile and quality of life (QoL) in patients with advanced HFpEF and nonreduced maximal inspiratory pressure (MIP).A total of 26 patients with HFpEF (median (interquartile range) age, peak exercise oxygen uptake (peak VO2) and left ventricular ejection fraction of 73 years (66-76), 10 ml/min/kg (7.6-10.5) and 72% (6…

Malemedicine.medical_specialtyTime Factorsanimal structuresEpidemiologyDiastoleBreathing ExercisesVentricular Function LeftWalking distanceDiastoleInternal medicinemedicineHumansElderly peopleIn patientProspective StudiesAgedHeart FailureExercise ToleranceEjection fractionbusiness.industryInspiratory muscle trainingStroke VolumeRecovery of FunctionMiddle AgedExercise capacityRespiratory MusclesTreatment OutcomeSpainExercise TestQuality of LifeCardiologyFemaleCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessBiomarkersEuropean Journal of Preventive Cardiology
researchProduct

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

2021

BACKGROUND Chronotropic incompetence has shown to be associated with a decrease in exercise capacity in heart failure with preserved ejection fraction (HFpEF), yet b-blockers are commonly used in HFpEF despite the lack of robust evidence. OBJECTIVES This study aimed to evaluate the effect of b-blocker withdrawal on peak oxygen consumption (peak VO2) in patients with HFpEF and chronotropic incompetence. METHODS This is a multicenter, randomized, investigator-blinded, crossover clinical trial consisting of 2 treatment periods of 2 weeks separated by a washout period of 2 weeks. Patients with stable HFpEF, New York Heart Association functional classes II and III, previous treatment with b-bloc…

medicine.medical_specialtyanimal structuresEjection fractionpeak Vo2chronotropic incompetencebusiness.industryChronotropic incompetencepercentage of predicted peakVo2Exercise capacitymedicine.diseaseHFpEFCrossover studyHeart failureInternal medicineHeart ratemedicineCardiologyβ-blockersheart ratecrossover trialCardiology and Cardiovascular MedicinePeak vo2Heart failure with preserved ejection fractionbusiness
researchProduct